Acelyrin Inc. (SLRN) NASDAQ
$4.39 (0.24) (-5.18%)
Market Cap: $434.73M
As of 05/17/24 04:00 PM EDT. Market closed.
Acelyrin Inc. (SLRN)
NASDAQ
$4.39
(0.24) (-5.18%)
Market Cap: $434.73M
As of 05/17/24 04:00 PM EDT. Market closed.
Add to Portfolio
... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
PRICE CHART FOR ACELYRIN INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$4.76
Previous Close
$4.63
Days Range
$4.37 - $4.67
52 week range
$4.14 - $29.88
Volume
742,134
Avg. Volume (30 days)
882,071
Market Cap
$434.73M
Dividend Yield
-
P/E
-
Shares Outstanding
99,026,983
Open
$4.76
Previous Close
$4.63
Days Range
$4.37 - $4.67
52 week range
$4.14 - $29.88
Volume
742,134
Avg. Volume (30 days)
882,071
Market Cap
$434.73M
Dividend Yield
-
P/E
-
Shares Outstanding
99,026,983
FINANCIAL STATEMENTS FOR ACELYRIN INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ACELYRIN INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Gloria Melanie | Chief Operating Officer | May 15, 2024 | Option Exercise | $4.47 | 10,298 | 46,032 | 130,286 | May 17, 2024, 07:12 PM |
| Kim Mina | Chief Executive Officer | May 15, 2024 | Option Exercise | $4.47 | 10,230 | 45,728 | 110,739 | May 17, 2024, 07:09 PM |
| Pangali Sanam | CLO & Head of People | May 15, 2024 | Option Exercise | $4.47 | 921 | 4,117 | 74,154 | May 17, 2024, 07:09 PM |
| Lin Shao-Lee | Chief Executive Officer | Apr 01, 2024 | Sale | $6.63 | 9,961 | 66,024 | 1,577,374 | Apr 03, 2024, 06:18 PM |
| Lin Shao-Lee | Chief Executive Officer | Feb 20, 2024 | Sale | $7.60 | 15,701 | 119,403 | 1,587,335 | Feb 22, 2024, 07:04 PM |
| Lin Shao-Lee | Chief Executive Officer | Jan 02, 2024 | Sale | $7.41 | 10,691 | 79,188 | 1,603,036 | Jan 04, 2024, 06:09 PM |
| Westlake BioPartners Fund II, L.P. | 10% Owner | May 09, 2023 | Buy | $18.00 | 1,250,000 | 22,500,000 | 9,790,729 | May 11, 2023, 09:16 PM |
| SEIDENBERG BETH C | Director | May 09, 2023 | Buy | $18.00 | 60,000 | 1,080,000 | 60,000 | May 11, 2023, 09:13 PM |
| SEIDENBERG BETH C | Director | May 09, 2023 | Buy | $18.00 | 1,250,000 | 22,500,000 | 9,790,729 | May 11, 2023, 09:13 PM |
| Svoronos Dawn | Director | May 09, 2023 | Buy | $18.00 | 15,000 | 270,000 | 15,000 | May 11, 2023, 09:11 PM |
| Gosebruch Henry O | Director | May 09, 2023 | Buy | $18.00 | 50,000 | 900,000 | 50,000 | May 11, 2023, 09:06 PM |
| Becker Daniel J. | Director | May 09, 2023 | Buy | $18.00 | 3,000 | 54,000 | 3,000 | May 11, 2023, 09:02 PM |
| Oyston Ronald | Chief People Officer | May 09, 2023 | Buy | $18.00 | 26 | 468 | 26 | May 11, 2023, 09:00 PM |
| Oyston Ronald | Chief People Officer | May 09, 2023 | Buy | $18.00 | 1,000 | 18,000 | 1,000 | May 11, 2023, 09:00 PM |
| Kim Mina | Chief Legal & Admin. Officer | May 09, 2023 | Buy | $18.00 | 5,000 | 90,000 | 5,000 | May 11, 2023, 08:58 PM |
| Peloso Paul | Chief Medical Officer | May 09, 2023 | Buy | $18.00 | 6,000 | 108,000 | 6,000 | May 11, 2023, 08:54 PM |
| Dier Mardi | CFO and CBO | May 09, 2023 | Buy | $18.00 | 1,750 | 31,500 | 875 | May 11, 2023, 08:51 PM |
| Dier Mardi | CFO and CBO | May 09, 2023 | Buy | $18.00 | 5,556 | 100,008 | 5,556 | May 11, 2023, 08:51 PM |
| Lin Shao-Lee | Chief Executive Officer | May 09, 2023 | Option Exercise | $24.69 | 337,179 | 8,324,950 | 770,034 | May 11, 2023, 08:50 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Gloria Melanie | Chief Operating Officer | 05/15/2024 | 46,032 |
| Kim Mina | Chief Executive Officer | 05/15/2024 | 45,728 |
| Pangali Sanam | CLO & Head of People | 05/15/2024 | 4,117 |
| Lin Shao-Lee | Chief Executive Officer | 04/01/2024 | 66,024 |
| Lin Shao-Lee | Chief Executive Officer | 02/20/2024 | 119,403 |
| Lin Shao-Lee | Chief Executive Officer | 01/02/2024 | 79,188 |
| Westlake BioPartners Fund II, L.P. | 10% Owner | 05/09/2023 | 22,500,000 |
| SEIDENBERG BETH C | Director | 05/09/2023 | 1,080,000 |
| SEIDENBERG BETH C | Director | 05/09/2023 | 22,500,000 |
| Svoronos Dawn | Director | 05/09/2023 | 270,000 |
| Gosebruch Henry O | Director | 05/09/2023 | 900,000 |
| Becker Daniel J. | Director | 05/09/2023 | 54,000 |
| Oyston Ronald | Chief People Officer | 05/09/2023 | 468 |
| Oyston Ronald | Chief People Officer | 05/09/2023 | 18,000 |
| Kim Mina | Chief Legal & Admin. Officer | 05/09/2023 | 90,000 |
| Peloso Paul | Chief Medical Officer | 05/09/2023 | 108,000 |
| Dier Mardi | CFO and CBO | 05/09/2023 | 31,500 |
| Dier Mardi | CFO and CBO | 05/09/2023 | 100,008 |
| Lin Shao-Lee | Chief Executive Officer | 05/09/2023 | 8,324,950 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ACELYRIN INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BLACKROCK INC. | 4,792,730 | 0.00075% | 64.84% | Other |
| ORBIMED ADVISORS LLC | 4,001,711 | 0.49% | No change | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,280,000 | 0.04% | 1722.22% | Other |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,906,629 | 3.35% | No change | Growth, Growth At A Reasonable Price |
| PALO ALTO INVESTORS LP | 1,715,180 | 1.31% | New | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 1,229,995 | 0.00077% | 58.89% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 125,018 | 0.00133% | New | Other |
| OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) | 71,412 | 0.03% | 19.02% | Value |
| ALPS ADVISORS INC | 68,659 | 0.00328% | 6.24% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 53,323 | 0.00063% | New | Event Driven |
CHANGE IN SHARES OUTSTANDING FOR ACELYRIN INC
STOCK BUYBACKS FOR ACELYRIN INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
06/30/2023
7.73%
2Q
BUYBACK ANNOUNCEMENT(S) FOR ACELYRIN INC
LOADING...